Document 2863
 DOCN  M94A2863
 TI    AZT monotherapy compared to AZT+DDC combined antiviral therapy and
       AZT+DDC+NAC (100 patients each group).
 DT    9412
 AU    Feregrino-Goyos M; Eid Lidt G; Gallegos Perez H; Alvarado DR; Mino LD;
       Clinica ISI de Norteamerica, Mexico D.F., Mexico.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):208 (abstract no. PB0260). Unique
       Identifier : AIDSLINE ICA10/94369712
 AB    OBJECTIVES: Comparison of the clinical response to three different
       antiviral schematic in HIV patients with less than 500 CD4 (Stages II,
       III, and IV del CDC). METHODS: During one year, 300 HIV patients with
       less than 500 CD4 were studied. Group I 100 patients received daily 500
       mg of AZT. Group II 100 patients received daily doses of 500 mg AZT +
       2.25 mg of DDC. Group III 100 patients, received 500 mg AZT + 2.25 mg
       DDC + 1500 mg of oral N-acetylcysteine. At the beginning and every 4
       months of the study, Aids defining events as PNC, CMV, S.K.,
       Cryptosporidiosis, etc., the age, CD4 count; p24 antigen levels,
       Karnofsky index and mortality were evaluated. Statistic study was done
       with parametric and non parametric tests. RESULTS: The age was 35, 37
       and 36 respectively (p > 0.05), Karnofsky index 88, 79 and 78 (0 < 0.05)
       CD4 were 247, 175 and 147 (p < 0.05), antigens p24 were 8.6, 9.7 and
       8.13 (p > 0.05) and previous defining events of AIDS were 56, 62 and 62
       (p < 0.05). At the end of the year 32% of Group I died, 11% of Group II
       and 11% of Group III (p < 0.05). New defining+ events of AIDS manifested
       themselves in 62, 32 and 23% of the cases (p < 0.05). Antigen p24
       decreased only in Groups II and III but non significantly. Cells count
       CD4 evolved each 4 months thus: in Group I, from 247.2, to 270.4, 236.2
       and 180.8 (p < 0.05). In group II it augmented from 175.3 to 231, 286.3
       and 293.8 (p < 0.05) and in the Group III it changed from 147.6 to
       241.3, 303.3 and 356.6 (p < 0.05). The Karnofsky index was increasing
       only in groups II and III. The most impressing results were to be
       observed in patients with CD4 higher than 200. CONCLUSIONS: In our
       patients, the combined therapy of AZT+DDC and AZT+DDC+NAC had better
       effect on the evolution of the patients in comparison with the Group
       treated only with AZT after one year with impressing results in
       mortality rates and CD4 counts and Karnofsky index.
 DE    Acetylcysteine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE  Acquired
       Immunodeficiency Syndrome/MORTALITY/PREVENTION & CONTROL  Adult
       AIDS-Related Opportunistic Infections/PREVENTION & CONTROL  Comparative
       Study  Drug Therapy, Combination  Human  HIV Infections/*DRUG THERAPY
       Karnofsky Performance Status  Treatment Outcome
       Zalcitabine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE
       Zidovudine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE  CLINICAL TRIAL
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).